The intersection of vector biology, gene therapy, and hemophilia. Issue 6 (1st September 2021)

• Record Type: Journal Article
• Authors: Lisowski, Leszek; Staber, Janice M.; Wright, J. Fraser; Valentino, Leonard A.
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 5:Issue 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-01
• Subjects: gene therapy -- hemophilia -- recombinant adeno‐associated viral (rAAV) vectors -- vector; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12586
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Gene therapy is at the forefront of the drive to bring the potential of cure to patients with genetic diseases. Multiple mechanisms of effective and efficient gene therapy delivery (eg, lentiviral, adeno‐associated) for transgene expression as well as gene editing have been explored to improve vector and construct attributes and achieve therapeutic success. Recent clinical research has focused on recombinant adeno‐associated viral (rAAV) vectors as a preferred method owing to their naturally occurring vector biology characteristics, such as serotypes with specific tissue tropisms, facilitated in vivo delivery, and stable physicochemical properties. For those living with hereditary diseases like hemophilia, this potential curative approach is balanced against the need to provide safe, predictable, effective, and durable factor expression. While in vivo studies of rAAV gene therapy have demonstrated amelioration of the bleeding phenotype in adults, long‐term safety and effectiveness remain to be established. This review discusses vector biology in the context of rAAV‐based liver‐directed gene therapy for hemophilia and provides an overview of the types of viral vectors and vector components that are under investigation, as well as an assessment of the challenges associated with gene therapy delivery and durability of expression.